Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2025-11-04 00:00:00 ET · period of report 2025-11-01 · accession 0001567160-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-04 | 2025-11-04 | NBIX | Gano Kyle | CEO, Dir | S - Sale+OE | $141.97 | -300 | 140.4K | -0.2% | -$42.6K |
| D | 2025-11-04 | 2025-11-01 | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +613 | 140.7K | +0.4% | $0 |
| D | 2025-11-04 | 2025-11-01 | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | -613 | 1,842 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-04 | S | D | 300 | $141.97 | 140,407 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-01 | M | A | 613 | $0.00 | 140,720 | D | — | — | (F1) Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 3 | Derivative | Restricted Stock Unit | 2025-11-01 | M | D | 613 | $0.00 | 1,842 | D | — · — to — | 613 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F4) This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award. |